Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 4 of 4 for “"NEDD9"”.

  1. The role of NEDD9 in TGFβ mediated tumour initiating cell dynamics in the Claudin-low breast cancer subtype

    … through the ability of the scaffolding protein NEDD9 to unite the TGFβ/SMAD and Rho-Actin-SRF pathways. Previously, oncogenicity has been ascribed to the level of NEDD9 protein expression. However, my analysis indicates this mediation by NEDD9 is irrespective of NEDD9 protein expression, which …

    cambridge Repository record for The role of NEDD9 in TGFβ mediated tumour initiating cell dynamics in the Claudin-low breast cancer subtype (opens in a new tab)

  2. Untersuchungen zu Bedeutung von TGF-β während der Entwicklung des Vorderhirns

    … Zellen spielen, wie Gata2, Runx1, Id3 und Nedd9. Die nähere Untersuchung der Auswirkungen eines Funktionsverlustes der Zielgene Ctgf, Gata2, Runx1 und Nedd9 auf die TGF-β induzierte Neurogenese identifizierte Nedd9 als notwendige Signal-Komponente während dieses Prozesses. Die Expression …

    goettingen Repository record for Untersuchungen zu Bedeutung von TGF-β während der Entwicklung des Vorderhirns (opens in a new tab)

  3. EBV-Associated Gastric Cancer: From Initial Infection to Unique Therapeutic Approaches

    … mutant gastric cancers. I found that loss of NEDD9 or inhibition of BCL-XL rendered cells hyper-sensitive to the PI3Ka inhibitor BYL719. Additionally, I found that loss of CBFB conferred resistance to BYL719 through up- regulation of the protein kinase PIM1 and defined the clinical utility of …

    duke Repository record for EBV-Associated Gastric Cancer: From Initial Infection to Unique Therapeutic Approaches (opens in a new tab)

  4. Defining Determinants of Primary Drug Resistance in Precision Cancer Therapies

    … in gastric cancer may be mediated by BCL-xL and NEDD9. Sensitization to PI3K-alpha inhibition by BCL-xL specific inhibitor revealed a novel targeted approach for the treatment of EBV+ PIK3CA mutant gastric cancers, thereby overcoming a perplexing obstacle to the effective targeting of PI3K …

    duke Repository record for Defining Determinants of Primary Drug Resistance in Precision Cancer Therapies (opens in a new tab)